Search

Bridgebio Pharma Inc

Gesloten

SectorGezondheidszorg

82.7 -1.44

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

82

Max

83.37

Belangrijke statistieken

By Trading Economics

Inkomsten

24M

-167M

Verkoop

40M

195M

EPS

-0.84

Winstmarge

-85.626

Werknemers

834

EBITDA

68M

-113M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+26.98% upside

Dividenden

By Acuity

Volgende Winsten

4 aug 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

2.9B

16B

Vorige openingsprijs

84.14

Vorige sluitingsprijs

82.7

Nieuwssentiment

By Acuity

34%

66%

88 / 342 Rangschikking in Healthcare

Bridgebio Pharma Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

15 jul 2026, 23:52 UTC

Correlated Moves
Social Media
News

Western Digital shares fell after hours, closing at about $513.97. Option traders showed bearish sentiment, with puts outpacing calls in volume.

15 jul 2026, 23:26 UTC

News

Synopsys shares are higher in after-market hours following a Buy rating from analyst Gary Mobley, who set a price target of $570.

15 jul 2026, 23:16 UTC

Social Media
News

PayPal Holdings Inc. shares are lower in after-market trading amid uncertainty over a $53 billion acquisition offer from Stripe and Advent International.

15 jul 2026, 23:11 UTC

Correlated Moves
News

The CHF/HKD exchange rate is trading higher, influenced by a decline in the US Producer Price Index and a stronger NY Empire State Manufacturing Index.

15 jul 2026, 23:06 UTC

Social Media
News

Wedbush initiates coverage on eBay with an Outperform rating. Shares are higher in after-hours trading following positive sentiment and acquisition news.

15 jul 2026, 23:06 UTC

News

American Airlines Group shares are lower in after-market hours following the appointment of John W. Dietrich to its board amid rising fuel price concerns.

15 jul 2026, 23:06 UTC

News

Vanguard Total Bond Market ETF is slightly higher in after-market hours, reflecting cautious investor sentiment amid escalating Middle East tensions and oil supply concerns.

15 jul 2026, 23:02 UTC

News
Social Media
Event

United Airlines Holdings shares fell in after-hours trading despite reporting strong second-quarter earnings of $1.99 per share and revenue of $17.67 billion.

15 jul 2026, 23:01 UTC

Social Media
News

J.B. Hunt Transport Services shares rose in after-market trading following strong second-quarter results, with revenues up 19% to $3.50 billion and EPS of $1.91.

15 jul 2026, 23:01 UTC

News

Wedbush initiated coverage on Booking Holdings with an Outperform rating. Shares are higher in after-market trading following a close at $174.85.

15 jul 2026, 22:16 UTC

News

Micron Technology will participate in the KeyBanc Capital Markets Technology Leadership Forum on August 10, 2026. Shares are higher in after-hours trading.

15 jul 2026, 20:14 UTC

ETF Constituents
News
Correlated Moves

The Vanguard Large-Cap ETF is lower in after-market hours, influenced by slight declines in major holdings like Microsoft and Apple amid mixed U.S. equity performance.

15 jul 2026, 20:07 UTC

News

Bitcoin's price is declining amid broader market sentiment shifts following softer inflation readings. Geopolitical tensions may also be influencing the cryptocurrency market.

15 jul 2026, 20:07 UTC

News
Correlated Moves

Microchip Technology shares are lower today, following a broader Nasdaq decline. Ongoing U.S.-Iran tensions continue to affect overall investor sentiment.

15 jul 2026, 20:07 UTC

News

Ethereum is trading higher, continuing an upward trend since Tuesday. The U.S. Producer Price Index decline has eased inflation concerns and boosted market sentiment.

15 jul 2026, 20:07 UTC

News

Bitcoin's price is lower today, influenced by softer inflation data and ongoing geopolitical tensions, despite earlier gains above Tuesday's close.

15 jul 2026, 20:06 UTC

News

Charter Communications shares rose following Liberty Broadband's $17.65 million insider sale of 129,907 shares, despite a recent revenue decline.

15 jul 2026, 20:03 UTC

Social Media
News

Amazon.com Inc is higher today, driven by a partnership with Herotel for satellite internet services and leadership changes within Amazon Web Services.

15 jul 2026, 20:02 UTC

Social Media
News
Macro Event

CSX shares are lower as Benchmark cuts its price target to $4 from $48, while Citizens initiates coverage with a Market Perform rating.

15 jul 2026, 20:02 UTC

News

Cisco Systems Inc shares are lower, hitting a nine-week low of 111.29 USD amid a broader decline in the Communications Equipment sub-sector.

15 jul 2026, 20:02 UTC

News

Workday Inc. shares are higher, supported by positive sentiment after a drop in the U.S. Producer Price Index, easing inflation concerns and interest rate hike expectations.

15 jul 2026, 20:02 UTC

Social Media
News

Apple Inc. shares rose after regulatory approval for its generative AI service in China and Citibank's price target increase to $365 amid market challenges.

15 jul 2026, 20:02 UTC

Correlated Moves
News
Macro Event
Social Media

Lam Research shares are lower as the Semiconductor Materials & Equipment sector declines. UBS raised its price target to $435, despite negative sentiment from insider selling.

15 jul 2026, 20:02 UTC

Social Media
Macro Event
Event
News

Cintas Corp's stock rises following strong fiscal fourth-quarter results, with revenue of $2.91 billion and GAAP EPS of $1.26 exceeding analyst expectations.

15 jul 2026, 20:02 UTC

Correlated Moves
Social Media
Macro Event
News

Applied Materials Inc shares are lower today amid mixed assessments, despite UBS raising its price target to $705. The stock's recent surge raises investor caution.

15 jul 2026, 19:56 UTC

News
Social Media

Broadcom faces EU scrutiny over VMware practices, yet shares are higher amid positive sentiment for hardware makers and AI demand.

15 jul 2026, 19:56 UTC

News
Social Media

MercadoLibre shares are lower as Bronstein, Gewirtz & Grossman, LLC announces an investigation into potential claims following extended loan term disclosures.

15 jul 2026, 19:56 UTC

News

Electronic Arts is rising amid reports of increased confidence in regulatory approval for its $55 billion acquisition at $210 per share.

15 jul 2026, 19:53 UTC

News
Social Media
Macro Event

Microsoft shares are higher today as Evercore ISI raised its price target to $525. Analysts remain optimistic ahead of the upcoming earnings report.

15 jul 2026, 19:52 UTC

News
Social Media

Alphabet Inc shares are higher, boosted by Warren Buffett's endorsement and plans for third-party stores in its App Store. Anticipation for earnings also supports momentum.

Peer Vergelijking

Prijswijziging

Bridgebio Pharma Inc Prognose

Koersdoel

By TipRanks

26.98% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 106.78 USD  26.98%

Hoogste 157 USD

Laagste 82 USD

Gebaseerd op 19 Wall Street-analisten die 12-maands prijsdoelen bieden voor Bridgebio Pharma Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

19 ratings

18

Buy

1

Hold

0

Sell

Sentiment

By Acuity

88 / 342 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Bridgebio Pharma Inc

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.
help-icon Live chat